专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08180574B2 Simplified peritoneal equilibration test for peritoneal dialysis 有权
标题翻译：腹膜透析简化腹膜平衡试验
公开(公告)号：US08180574B2
公开(公告)日：2012-05-15
申请号：US12498847
申请日：2009-07-07
申请人： Ying-Cheng Lo , Alp Akonur , Sarah Stobo Prichard
发明人： Ying-Cheng Lo , Alp Akonur , Sarah Stobo Prichard
IPC分类号： G01N33/48 , G06F19/00
CPC分类号： A61M1/28 , A61M1/1619
摘要： A simplified peritoneal equilibration test (S-PET) is disclosed. Instead of a lengthy peritoneal equilibration test (PET), the simplified procedure requires no blood sample and may use data from as few as two or three samples to classify a peritoneal membrane of a user. Typically, a peritoneal membrane or peritoneum of a dialysis patient, or other person, is classed as a high transport membrane, high-average transport membrane, a low-average transport membrane or a low transporter membrane. The S-PET may be performed at home by a user without the need to submit a blood sample. Kits for analyzing the samples may be furnished for home use. The kits may use disposable strips, microfluidic analyzers or chemical reagents, or may alternatively include reusable analysis equipment, such as optical or conductivity analysis equipment.
摘要翻译：公开了一种简化的腹膜平衡试验（S-PET）。代替长时间的腹膜平衡试验（PET），简化的程序不需要血液样品，并且可以使用少至两个或三个样品的数据来分类用户的腹膜。通常，透析患者或其他人的腹膜或腹膜被分类为高运输膜，高平均运输膜，低平均运输膜或低转运膜。 S-PET可以由用户在家进行，而不需要提交血样。用于分析样品的试剂盒可供家庭使用。试剂盒可以使用一次性条，微流控分析仪或化学试剂，或者可以替代地包括可重复使用的分析设备，例如光学或电导率分析设备。

2. 发明申请

US20110010101A1 SIMPLIFIED PERITONEAL EQUILIBRATION TEST FOR PERITONEAL DIALYSIS 有权
标题翻译：简单的PERITONEAL EQUILIBRATION测试用于腹膜透析
公开(公告)号：US20110010101A1
公开(公告)日：2011-01-13
申请号：US12498847
申请日：2009-07-07
申请人： Ying-Cheng Lo , Alp Akonur , Sarah Stobo Prichard
发明人： Ying-Cheng Lo , Alp Akonur , Sarah Stobo Prichard
IPC分类号： G06F19/00
CPC分类号： A61M1/28 , A61M1/1619
摘要： A simplified peritoneal equilibration test (S-PET) is disclosed. Instead of a lengthy peritoneal equilibration test (PET), the simplified procedure requires no blood sample and may use data from as few as two or three samples to classify a peritoneal membrane of a user. Typically, a peritoneal membrane or peritoneum of a dialysis patient, or other person, is classed as a high transport membrane, high-average transport membrane, a low-average transport membrane or a low transporter membrane. The S-PET may be performed at home by a user without the need to submit a blood sample. Kits for analyzing the samples may be furnished for home use. The kits may use disposable strips, microfluidic analyzers or chemical reagents, or may alternatively include reusable analysis equipment, such as optical or conductivity analysis equipment.
摘要翻译：公开了一种简化的腹膜平衡试验（S-PET）。代替长时间的腹膜平衡试验（PET），简化的程序不需要血液样品，并且可以使用少至两个或三个样品的数据来分类用户的腹膜。通常，透析患者或其他人的腹膜或腹膜被分类为高运输膜，高平均运输膜，低平均运输膜或低转运膜。 S-PET可以由用户在家进行，而不需要提交血样。用于分析样品的试剂盒可供家庭使用。试剂盒可以使用一次性条，微流控分析仪或化学试剂，或者可以替代地包括可重复使用的分析设备，例如光学或电导率分析设备。

3. 发明申请

US20100217178A1 PREDICTION OF PERITONEAL DIALYSIS THERAPY OUTCOMES USING DIALYSATES MIXED AT DIFFERENT GLUCOSE CONCENTRATIONS 审中-公开
标题翻译：使用在不同葡萄糖浓度下混合的透析液来预测眼底透析治疗的成果
公开(公告)号：US20100217178A1
公开(公告)日：2010-08-26
申请号：US12389751
申请日：2009-02-20
申请人： Ying-Cheng Lo , Alp Akonur , Isaac Martis , Andrew C. Hayes
发明人： Ying-Cheng Lo , Alp Akonur , Isaac Martis , Andrew C. Hayes
IPC分类号： A61M1/28 , G06N5/02 , G06F17/10 , G06G7/60
CPC分类号： A61M1/28 , A61M1/1613 , A61M1/287 , G06F19/3481 , G16H50/50
摘要： A method for peritoneal dialysis treatment includes (i) predicting results of a plurality of patient therapy outcomes for a plurality of different mixed dextrose level dialysis solutions; (ii) selecting one of the mixed dextrose level solutions for a patient based on the results; and (iii) performing at least one therapy using different unmixed dextrose level solutions that combine to simulate a like cumulative concentration that would be achieved using the selected mixed dextrose level solution.
摘要翻译：腹膜透析治疗的方法包括（i）预测多种不同混合葡萄糖水平透析溶液的多种患者治疗结果的结果; （ii）基于结果选择患者的混合葡萄糖水平溶液之一; 和（iii）使用不同混合葡萄糖水平溶液进行至少一种治疗，其组合以模拟使用所选择的混合葡萄糖水平溶液将达到的类似累积浓度。

4. 发明授权

US08926551B2 Peritoneal dialysis therapy with large dialysis solution volumes 有权
标题翻译：腹膜透析治疗大量透析液量
公开(公告)号：US08926551B2
公开(公告)日：2015-01-06
申请号：US12498853
申请日：2009-07-07
申请人： Ying-Cheng Lo , Alp Akonur , Yuanpang S. Ding
发明人： Ying-Cheng Lo , Alp Akonur , Yuanpang S. Ding
IPC分类号： A61M1/00 , A61M1/28
CPC分类号： A61M1/28 , A61M1/282
摘要： Patients suffering from acute renal failure must be diagnosed and treated quickly so that a physician can confidently prescribe either peritoneal dialysis or hemodialysis. In one way of quickly treating the patients, software is used to calculate a suitable peritoneal dialysis prescription without regard to how short or how long a dialysis cycle is used, and without regard to a total dialysate fluid volume for a therapy. For patients with suitable peritoneal membrane transport properties, the software program suggests that, at least over a short period of time, unexpectedly high ultrafiltrate volumes and high clearances may be achieved.
摘要翻译：患急性肾衰竭的患者必须迅速诊断和治疗，以便医生可以自信地开出腹膜透析或血液透析。以快速治疗患者的一种方式，使用软件来计算合适的腹膜透析处方，而不考虑使用透析循环的短暂或多长时间，并且不考虑用于治疗的总透析液体积。对于具有适当腹膜转运性质的患者，软件程序表明，至少在短时间内，可能会实现出乎意料的高超滤液体积和高清除率。

5. 发明授权

US08521482B2 Simulation of patient drain phase in peritoneal dialysis 有权
标题翻译：模拟腹膜透析患者排水期
公开(公告)号：US08521482B2
公开(公告)日：2013-08-27
申请号：US12389886
申请日：2009-02-20
申请人： Alp Akonur , Ying-Cheng Lo
发明人： Alp Akonur , Ying-Cheng Lo
IPC分类号： G06F7/60
CPC分类号： G16H50/50 , A61M1/28 , A61M1/282
摘要： A method of modeling a patient's peritoneal dialysis drain phase includes (i) modeling a first segment of a drain phase curve as having a constant flowrate; (ii) modeling a second segment of a drain phase curve as having a decaying exponential flowrate; and (iii) incorporating a switching component into the first and second components so that (a) at a first time the first segment is active and while the second segment is inactive and (b) at a second time the first segment is inactive and while the second segment is active.
摘要翻译：建模患者腹膜透析排泄阶段的方法包括（i）将排水相曲线的第一段建模为具有恒定的流速; （ii）将排水相曲线的第二段建模为具有衰减指数流速; 以及（iii）将切换组件并入到所述第一和第二组件中，使得（a）在第一时间第一段处于活动状态，而第二段处于非活动状态，并且（b）在第二时间段，第一段无效，而第二段是活跃的。

6. 发明申请

US20110009810A1 PERITONEAL DIALYSIS THERAPY WITH LARGE DIALYSIS SOLUTION VOLUMES 有权
标题翻译：大量透析溶液的腹膜透析治疗
公开(公告)号：US20110009810A1
公开(公告)日：2011-01-13
申请号：US12498853
申请日：2009-07-07
申请人： Ying-Cheng Lo , Alp Akonur , Yuanpang S. Ding
发明人： Ying-Cheng Lo , Alp Akonur , Yuanpang S. Ding
IPC分类号： A61M1/28
CPC分类号： A61M1/28 , A61M1/282
摘要： Patients suffering from acute renal failure must be diagnosed and treated quickly so that a physician can confidently prescribe either peritoneal dialysis or hemodialysis. In one way of quickly treating the patients, software is used to calculate a suitable peritoneal dialysis prescription without regard to how short or how long a dialysis cycle is used, and without regard to a total dialysate fluid volume for a therapy. For patients with suitable peritoneal membrane transport properties, the software program suggests that, at least over a short period of time, unexpectedly high ultrafiltrate volumes and high clearances may be achieved.
摘要翻译：患急性肾衰竭的患者必须迅速诊断和治疗，以便医生可以自信地开出腹膜透析或血液透析。以快速治疗患者的一种方式，使用软件来计算合适的腹膜透析处方，而不考虑使用透析循环的短暂或多长时间，并且不考虑用于治疗的总透析液体积。对于具有适当腹膜转运性质的患者，软件程序表明，至少在短时间内，可能会实现出乎意料的高超滤液体积和高清除率。

7. 发明授权

US08868350B2 Therapy prediction and optimization for renal failure blood therapy, especially home hemodialysis 有权
公开(公告)号：US08868350B2
公开(公告)日：2014-10-21
申请号：US13088044
申请日：2011-04-15
申请人： Alp Akonur , John Kenneth Leypoldt , Ying-Cheng Lo , Baris Ugur Agar
发明人： Alp Akonur , John Kenneth Leypoldt , Ying-Cheng Lo , Baris Ugur Agar
IPC分类号： G01N33/48 , A61M1/16 , A61M1/36 , G06F19/00
CPC分类号： A61M1/1603 , A61M1/16 , A61M1/1611 , A61M1/1613 , A61M1/1619 , A61M1/3609 , A61M2202/0498 , A61M2205/15 , A61M2205/3584 , A61M2205/50 , A61M2205/502 , A61M2205/52 , A61M2230/20 , G06F19/3481
摘要： A method of predicting serum phosphorus concentrations in a patient during hemodialysis includes measuring serum phosphorus concentrations of the patient over a hemodialysis treatment session time and an ultrafiltration rate calculated by a difference between pre- and post-dialytic body weight of the patient during an initial hemodialysis treatment session divided by a total treatment time of the treatment session and estimating a phosphorous mobilization clearance and a pre-dialysis distribution volume of phosphorus for the patient. Serum phosphorus concentrations of the patient can then be predicted at any time during any hemodialysis treatment session with the estimated phosphorous mobilization clearance and pre-dialysis distribution volume of phosphorus of the patient.

8. 发明授权

US08845570B2 Therapy prediction and optimization for renal failure blood therapy, especially home hemodialysis 有权
标题翻译：肾衰竭血液治疗的治疗预测和优化，特别是家庭血液透析
公开(公告)号：US08845570B2
公开(公告)日：2014-09-30
申请号：US13088064
申请日：2011-04-15
申请人： Alp Akonur , John Kenneth Leypoldt , Ying-Cheng Lo , Baris Ugar Agar
发明人： Alp Akonur , John Kenneth Leypoldt , Ying-Cheng Lo , Baris Ugar Agar
IPC分类号： A61M37/00 , A61M1/16 , A61M1/36 , G06F19/00
CPC分类号： A61M1/1603 , A61M1/16 , A61M1/1611 , A61M1/1613 , A61M1/1619 , A61M1/3609 , A61M2202/0498 , A61M2205/15 , A61M2205/3584 , A61M2205/50 , A61M2205/502 , A61M2205/52 , A61M2230/20 , G06F19/3481
摘要： A method of predicting serum phosphorus concentrations in a patient during hemodialysis includes measuring serum phosphorus concentrations of the patient over a hemodialysis treatment session time and an ultrafiltration rate calculated by a difference between pre- and post-dialytic body weight of the patient during an initial hemodialysis treatment session divided by a total treatment time of the treatment session and estimating a phosphorous mobilization clearance and a pre-dialysis distribution volume of phosphorus for the patient. Serum phosphorus concentrations of the patient can then be predicted at any time during any hemodialysis treatment session with the estimated phosphorous mobilization clearance and pre-dialysis distribution volume of phosphorus of the patient.
摘要翻译：在血液透析期间预测患者血清磷浓度的方法包括测量血液透析治疗会话时间的患者的血清磷浓度，以及通过初始血液透析期间患者的透析前和透析后体重之间的差异计算的超滤率治疗时间除以治疗会话的总治疗时间，并估计患者的磷的移动清除率和磷酸盐的透析前分布体积。然后可以在任何血液透析治疗期间的任何时间预测患者的血清磷浓度，其中估计磷移动清除率和患者的磷的透析前分布体积。

9. 发明授权

US09348975B2 Optimizing therapy outcomes for peritoneal dialysis 有权
标题翻译：优化腹膜透析治疗效果
公开(公告)号：US09348975B2
公开(公告)日：2016-05-24
申请号：US12431458
申请日：2009-04-28
申请人： Ying-Cheng Lo , Alp Akonur , Isaac Martis
发明人： Ying-Cheng Lo , Alp Akonur , Isaac Martis
IPC分类号： G06F19/00 , A61M1/28
CPC分类号： G06F19/3481 , A61M1/28 , A61M1/281 , A61M1/282 , A61M2205/3569 , A61M2205/52 , A61M2205/6018 , A61M2205/6054 , A61M2205/6072 , G06F19/00
摘要： Peritoneal dialysis therapy outcomes have been calculated for a variety of dwell times of peritoneal dialysis fluids in the peritoneal cavities of dialysis patients using kinetic modeling. The length of dwell time should not be the same for every patient, but should vary according to the patient condition and needs. Some patients have a potential for expressing greater ultrafiltrate into the dialysis fluid, and these patients can benefit from a longer dwell time, whereas other patients with less potential will not benefit from a longer dwell time. An optimal or peak time is observed for each peritoneal dialysis therapy outcome, such as ultrafiltrate volume rate, urea clearance (Kt/V), and creatinine clearance, while minimizing hydrocarbon absorption. These values and input parameters can be used to tailor the peritoneal dialysis dwell time for each patient, estimating the peak dwell time that will yield the best therapy outcome for each patient.
摘要翻译：已经使用动力学模型计算了透析患者腹膜腔腹膜透析液的各种停留时间的腹膜透析治疗结果。每个患者的停留时间长度不应相同，但应根据患者情况和需要而变化。一些患者有可能在透析液中表达更多的超滤液，这些患者可以从更长的停留时间中受益，而潜在的潜力较小的患者不会受益于更长的停留时间。对于每个腹膜透析治疗结果，观察到最佳或高峰时间，例如超滤液体积率，尿素清除率（Kt / V）和肌酐清除率，同时使烃吸收最小化。这些值和输入参数可用于定制每个患者的腹膜透析停留时间，估计将为每位患者产生最佳治疗结果的峰值停留时间。

10. 发明申请

US20120029324A1 THERAPY PREDICTION AND OPTIMIZATION FOR RENAL FAILURE BLOOD THERAPY, ESPECIALLY HOME HEMODIALYSIS 有权
标题翻译：治疗失败血液治疗的治疗预防和优化，特别是家庭心脏病学
公开(公告)号：US20120029324A1
公开(公告)日：2012-02-02
申请号：US13088064
申请日：2011-04-15
申请人： Alp Akonur , John Kenneth Leypoldt , Ying-Cheng Lo , Baris Ugur Agar
发明人： Alp Akonur , John Kenneth Leypoldt , Ying-Cheng Lo , Baris Ugur Agar
IPC分类号： A61B5/15
CPC分类号： A61M1/1603 , A61M1/16 , A61M1/1611 , A61M1/1613 , A61M1/1619 , A61M1/3609 , A61M2202/0498 , A61M2205/15 , A61M2205/3584 , A61M2205/50 , A61M2205/502 , A61M2205/52 , A61M2230/20 , G06F19/3481
摘要： A method of predicting serum phosphorus concentrations in a patient during hemodialysis includes measuring serum phosphorus concentrations of the patient over a hemodialysis treatment session time and an ultrafiltration rate calculated by a difference between pre- and post-dialytic body weight of the patient during an initial hemodialysis treatment session divided by a total treatment time of the treatment session and estimating a phosphorous mobilization clearance and a pre-dialysis distribution volume of phosphorus for the patient. Serum phosphorus concentrations of the patient can then be predicted at any time during any hemodialysis treatment session with the estimated phosphorous mobilization clearance and pre-dialysis distribution volume of phosphorus of the patient.
摘要翻译：在血液透析期间预测患者血清磷浓度的方法包括测量血液透析治疗会话时间的患者的血清磷浓度，以及通过初始血液透析期间患者的透析前和透析后体重之间的差异计算的超滤率治疗时间除以治疗会话的总治疗时间，并估计患者的磷的移动清除率和磷酸盐的透析前分布体积。然后可以在任何血液透析治疗期间的任何时间预测患者的血清磷浓度，其中估计磷移动清除率和患者的磷的透析前分布体积。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式